Kairos Pharma, LTD. (KAPA)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Revenues | - | - | - | |
| Research and development | 496 | 493 | 14 | |
| General and administrative | 960 | 773 | 369 | |
| Total operating expenses | 1,456 | 1,266 | 383 | |
| Loss from operations | -1,456 | -1,266 | -383 | |
| Other nonoperating expense | - | - | 537 | |
| Interest income | 34 | 4 | - | |
| Interest expense | - | - | 12 | |
| Debt discount amortization | - | - | 115 | |
| Total other expenses, net | 34 | 4 | -664 | |
| Net loss | -1,422 | -1,262 | -1,047 | |
| Basic | 17,213,017 | 15,875,485 | 10,910,227 | |
| Basic loss per common share | -0.08 | -0.08 | -0.1 | |
| Diluted | 17,213,017 | 15,875,485 | 10,910,227 | |
| Diluted loss per common share | -0.08 | -0.08 | -0.1 | |